A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Trial Profile

A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms RASTEN
  • Most Recent Events

    • 02 Nov 2017 Protocol was amended to extend the study period due to a slower inclusion rate than initially expected, according to results published in the Annals of Oncology.
    • 02 Nov 2017 Primary endpoint of significant increase of overall survival has not been met, according to results published in the Annals of Oncology.
    • 02 Nov 2017 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top